Related Experiment Video
Updated: Dec 18, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Both sub-scales of the "Keratoconus End-Points Assessment Questionnaire" (KEPAQ) are unidimensional and reliable
Kepa Balparda1, Tatiana Herrera-Chalarca2, Sneider Alexander Torres-Soto3
1Department of Cornea and Refractive Surgery, Black Mammoth Surgical, Medellín, Colombia. kb@kepabalparda.com.
Background:
Measuring quality of life in keratoconus is important and demands for well-constructed instruments and scales. To date, the Keratoconus End-Points Assessment Questionnaire (KEPAQ) is the only disease-specific scale to measure both functional and emotional compromise due to disease. Nevertheless, not much information exists regarding whether both sub-scales of the test show unidimensionality, a necessary condition in well-functioning instruments.
Methods:
A sample of patients with a confirmed diagnosis of keratoconus were administered the full version of the KEPAQ. A Rasch analysis and principal component analysis were performed.
Results:
A total of 249 patients with keratoconus were included. Their average age was 29.19 ± 10.91 years, and 51.40% were male. Mean score for the KEPAQ-E was 2.51 ± 3.29 logit while it was 2.26 ± 3.70 logit for the KEPAQ-F. For both sub-scales, Kaiser Criterion, Scree Plot Criterion, and Variability Criterion demonstrated unidimensionality. Reliability as measured by Cronbach's alpha was 0.85 for the KEPAQ-E and 0.87 for the KEPAQ-F.
Conclusions:
The KEPAQ is a robust, well-designed disease-specific questionnaire that shows unidimensionality. It can be reliably used to measure quality of life in keratoconus patients.
More Related Videos
07:29Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
Published on: November 12, 2015
05:14Comparison of Agreement and Accuracy using Binocular Wavefront Optometer with Autorefractor and Phoropter
Published on: September 16, 2025